Projecting Market Access Success For Early-Stage Pharma Assets: Getting Past The Hurdles
All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.
You may also be interested in...
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.
The biopharma industry invests substantially in post-approval studies to convey information about the value of its products to constituents, but the majority of these efforts do not address core, real-world questions raised by payors. A new business model recognizing the strategic value of medical affairs to market access is needed to stem the tide of disappointing reimbursement decisions.
Can Europe's Approval And Value Reviews Work More In Concert? It's A Timesaver That Might Be A Long Time Coming
In recent years, European drug approval agencies and health technology assessment authorities had little interchange, reflecting mutual disregard at best, and mutual recrimination at worst, European Medicines Agency Senior Medical Officer Hans-Georg Eichler observed.